FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Other Events
Item8.01
| Other Events |
On January 30, 2017, FibroGen, Inc. issued a press release in
which it reported topline results from its two ongoing Phase 3
studies in China of roxadustat, its first-in-class, orally
administered small molecule for treatment of anemia in
dialysis-dependent and non-dialysis-dependent chronic kidney
disease patients.
A copy of such press release is furnished as Exhibit99.1 to this
report and is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
| 99.1 |
Press Release titled FibroGens Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China dated January 30, 2017 |
About FibroGen, Inc. (NASDAQ:FGEN)
FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies. FibroGen, Inc. (NASDAQ:FGEN) Recent Trading Information
FibroGen, Inc. (NASDAQ:FGEN) closed its last trading session up +0.10 at 23.30 with 405,011 shares trading hands.
